INTRODUCTION
■ Atypical antipsychotics are the mainstay of current treatment of acute episodes, symptom reduction, and relapse prevention in patients with schizophrenia. 1 However, most atypical antipsychotics are often associated with an increased risk of weight gain and other metabolic abnormalities.
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■ Atypical antipsychotic-induced side effects are among the main contributors to treatment discontinuation and relapse among patients with schizophrenia. [5] [6] [7] [8] ■ Current Scottish Intercollegiate Guideline Network (SIGN 131) clinical guidelines recommend olanzapine, risperidone or amisulpride as the preferred treatments in patients with an acute exacerbation or recurrence of schizophrenia, and for maintenance treatment.
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■ SIGN guidelines recommend aripiprazole (along with haloperidol or amisulpride) for adult patients with schizophrenia who are concerned about, or at risk of weight gain.
■ Lurasidone, a new atypical antipsychotic for the treatment of schizophrenia in adults, has been shown to effectively treat acute symptoms, prevent long-term relapse and have a favourable adverse events profile, including minimal effects on weight and metabolic parameters.
OBJECTIVES
■ The objective of this study was to conduct a cost-utility analysis (CUA) to compare lurasidone with aripiprazole, and a budget impact analysis of introducing lurasidone treatment to patients with schizophrenia in the Scottish setting.
METHODS

Cost-utility analysis
■ A Markov model with a 10-year horizon including a 6-week acute phase and a maintenance phase across three health states (discontinuation, relapse, and death), was developed ( Figure 1 ).
■ Based on the favourable adverse events profile of lurasidone, the patient population considered was those at risk of weight gain and cardiovascular and metabolic disease.
■ Patients entering the model in the acute phase were assumed to either:
─ initiate therapy and continue into long-term maintenance with a given therapy, or ─ discontinue initial therapy following a 6-week trial, switch to the next treatment and begin an additional 6-week trial.
■ Deterministic sensitivity analysis and probabilistic sensitivity analysis (DSA and PSA) were conducted.
Data source
■ Short-term risks (at week 6) of discontinuation and adverse events associated with lurasidone and aripiprazole, relative to placebo, were taken from an independent published network meta-analysis.
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■ Long-term risk of discontinuation and relapse for lurasidone were taken from Study D1050234, a 12 month, randomised, double-blind, active-controlled study versus quetiapine XR. 16 to inform the utility decrement of diabetes.
■ In addition to weight gain and extrapyramidal symptoms, the long-term impact of diabetes on health-related quality-of-life (utilities) was included.
Costs
■ Costs included drug therapy, costs of relapse, and costs of outpatient, primary and residential care.
■ A 3.5% annual discount rate was applied to costs and benefits; the perspective for costs was that of the National Health Service and personal and social services in Scotland.
Budget impact analysis
■ A 5-year time horizon was considered to project the difference in acquisition costs per patient per year (PPPY) between lurasidone and those medicines estimated to be displaced by lurasidone.
■ The uptake rate of lurasidone was assumed to be approximately 66% of that seen for aripiprazole in its first five years in the UK.
RESULTS
■ The base case CUA indicated that lurasidone was associated with an overall cost saving of £3,383 per patient and an increase of 0.005 quality-adjusted lifeyears (QALYs), meaning that lurasidone was a dominant strategy versus aripiprazole (Table 1) .
■ The DSA revealed that the analysis was robust and the results were most sensitive to relapse rates.
■ Based on the PSA, the probability of lurasidone being a cost-effective strategy was approximately 75% at all willingness-to-pay thresholds (Figure 2 ). ■ Although total drug acquisition costs were £416 higher per patient treated with lurasidone, these were offset by reduced costs of CRHTT relapse and inpatient relapse (£2,821 and £1,121, respectively), switching (£17), and adverse events (£50). 
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